January 30, 2023 11:32 AM ESTUpdated February 7, 09:28 AM

#JPM23: Regulatory uncertainty? What about M&A? Data rule? Alessandro Maselli and John Carroll take out their crystal balls

John Carroll

Editor & Founder

Endpoints editor and founder John Carroll sat down the Catalent CEO Alessandro Maselli to talk about what’s ahead in 2023. Right or wrong, this covers …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

#JPM23: Regulatory uncertainty? What about M&A? Data rule? Alessandro Maselli and John Carroll take out their crystal balls

John Carroll

Editor & Founder

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Drugmakers see a substantial, but manageable, hit to business from tariffs. But the worst may lie ahead

Bristol Myers CEO signals dealmaking will be a top priority in 2025

Roche CEO warns that tariffs could impact dealmaking

Roche takes steps to protect itself from tariffs, while Sanofi hangs back

Sanofi's Altuviiio closing in on blockbuster status, Dupixent sales surge

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

#JPM23: Reg­u­la­to­ry un­cer­tain­ty? What about M&A? Da­ta rule? Alessan­dro Masel­li and John Car­roll take out their crys­tal balls

Editor & Founder

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

#JPM23: Regulatory uncertainty? What about M&A? Data rule? Alessandro Maselli and John Carroll take out their crystal balls